arrow_back Back to App

Pharmacy Addiction Care: Grants for Buprenorphine Treatment and Recovery Support.

This Act establishes a 3-year grant program to enable community pharmacies to provide comprehensive care for individuals with opioid and other substance use disorders. Citizens will gain easier access to addiction treatment, including buprenorphine, directly at pharmacies, significantly lowering barriers to therapy. Funds can be used for pharmacist training, private counseling spaces, medication costs, and telehealth services.
Key points
Easier Access to Treatment: Pharmacies will be able to offer buprenorphine and manage withdrawal, providing same-day, low-barrier care services.
Pharmacist-Physician Collaboration: The program requires collaborative practice agreements allowing pharmacists to manage drug therapy for addiction treatment.
Funding for Care: Grants will cover medication costs (up to a 30-day supply of buprenorphine), staff training, and construction of private spaces for counseling in pharmacies.
Reduced Barriers: Pharmacies must provide low-barrier treatment, including reduced or eliminated requirements for payment, insurance, age limits, and identification.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_4429
Sponsor: Sen. Booker, Cory A. [D-NJ]
Process start date: 2024-05-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

SUPPORT Rx Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_4429.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-05-23.

What are the main provisions?

Key points include:

  • Easier Access to Treatment: Pharmacies will be able to offer buprenorphine and manage withdrawal, providing same-day, low-barrier care services.
  • Pharmacist-Physician Collaboration: The program requires collaborative practice agreements allowing pharmacists to manage drug therapy for addiction treatment.
  • Funding for Care: Grants will cover medication costs (up to a 30-day supply of buprenorphine), staff training, and construction of private spaces for counseling in pharmacies.
  • Reduced Barriers: Pharmacies must provide low-barrier treatment, including reduced or eliminated requirements for payment, insurance, age limits, and identification.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Booker, Cory A. [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health